Developing Cancer Cures through the ASX | Going Public with Leslie Chong & Paul Hopper
With Stake, Australia's leading investing platform, I'm excited to share the 12th episode of 'Going Public' - a monthly series giving you unique access to the entrepreneurs, founders and executives who've taken their business public.
In this episode of the Going Public series, Mark learns about the remarkable journey of Imugene Ltd (ASX: IMU), a clinical-stage immuno-oncology company revolutionising cancer treatment with cutting-edge immunotherapies. Join us as we explore how CEO Leslie Chong has helped transform Imugene from a single-technology startup to a biotech leader with five active clinical trials targeting various cancers. Discover the strategic moves that propelled the company's market cap from $10 million to $500 million and secured its place in the ASX Top 300. We'll also hear from Executive Chairman Paul Hopper, the mastermind behind the IMU listing and successful IPOs for Radiopharm (RAD) and Chimeric (CHM). This episode offers invaluable insights into the world of biotech, innovation, and the path to IPO success.
DISCLAIMER:
Views expressed are those of the individual only. This does not constitute financial advice.
You can subscribe to the newsletter here: https://lnkd.in/e7C8akgj.
Follow Mark Bouris on Instagram, LinkedIn & YouTube.
See omnystudio.com/listener for privacy information.
See omnystudio.com/listener for privacy information.